Skip to main content
. Author manuscript; available in PMC: 2011 Mar 17.
Published in final edited form as: Vaccine. 2008 Jun 2;26(32):4062–4072. doi: 10.1016/j.vaccine.2008.05.018

Table 1.

Profiles of participants

Participant(s) Years HIV-1-infected CD4 count (/mm3) Viral Load (copies/ml) CD8 Epitope HAART
Pt 1 11 950 <50 B27/gag/KRWIILGLNK no
Pt 2 5 months 560 >500,000 B8/nef/FLKEKGGL no
Pt 3 9 820 158 A*0201/gag/SLYNTVATL no
Pt 4 2 330 200,000 A*0201/gag/SLYNTVATL no
Pt 5–7 HIV-1 negative NA NA A*0201/EBV/GLCLVAML NA

NA=not applicable

HAART= highly active anti-retroviral therapy